Document Detail


Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients.
MedLine Citation:
PMID:  23331429     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Recent studies have demonstrated that cytomegalovirus (CMV) infection and disease are associated with increased risk of graft loss and death in high-risk (donor CMV seropositive/recipient CMV seronegative) liver transplant recipients (LTR) despite effective antiviral chemoprophylaxis. Predictors of CMV infection and disease in this important population are incompletely defined. METHODS: A retrospective cohort study of 227 high-risk first LTR who received primary anti-CMV chemoprophylaxis during the first 100 days after transplant was performed. A large number of patient, donor, operative, and post-transplant potential risk factors were collected. Associations of potential risk factors for CMV infection or disease that occurred during the first year after transplant were assessed using Cox regression models. After Bonferroni adjustment for multiple testing, P-values ≤0.00125 (associations with CMV infection) and ≤0.00122 (associations with CMV disease) were considered as statistically significant. RESULTS: CMV infection and disease occurred in 91 (40%) and 43 (19%) of LTR, respectively. In multivariable analysis, increased risk of CMV infection was observed for patients with lower model for end-stage liver disease (MELD) score (P = 0.025), lower total bilirubin (P = 0.014), and longer operative time (P = 0.038), whereas increased risk of CMV disease was seen in patients with lower MELD score (P = 0.026), lower total bilirubin (P = 0.044), and lower international normalized ratio (P = 0.043). However, after adjustment for multiple testing, none of these findings approached statistical significance. CONCLUSION: Our results suggest that interventions designed to prevent CMV infection and disease should be applied to all high-risk LTR until more definitive predictors of these complications are identified.
Authors:
J G Katsolis; W Bosch; M G Heckman; N N Diehl; J A Shalev; S Pungpapong; T A Gonwa; W C Hellinger
Related Documents :
23738889 - Nk cells improve control of friend virus infection in mice persistently infected with m...
24478129 - Association of neutrophil to lymphocyte ratio with presence and severity of gastritis d...
23765259 - Methylation pattern of thbs1, gata-4, and hic1 in pediatric and adult patients infected...
24227849 - Expression profile of micrornas in epstein-barr virus-infected ags gastric carcinoma ce...
24488979 - Prevalence and risk factors of soil-transmitted helminth infection in nepal.
23821549 - Repression of inflammasome by francisella tularensis during early stages of infection.
11698389 - Analysis of early promoters of the bacillus bacteriophage ga-1.
25366819 - Increasing hiv-1 molecular complexity among msm in bangkok.
12902759 - Demonstration of metagonimus yokogawai metacercariae from plecoglossus altivelis in riv...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-18
Journal Detail:
Title:  Transplant infectious disease : an official journal of the Transplantation Society     Volume:  -     ISSN:  1399-3062     ISO Abbreviation:  Transpl Infect Dis     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883688     Medline TA:  Transpl Infect Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 John Wiley & Sons A/S.
Affiliation:
Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville, Florida, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of ?v?6 integrin and collagen fibre in oral squamous cell carcinoma: association with cli...
Next Document:  Alternate-day Dosing with Statins.